LIGAND PHARMACEUTICALS INC (LGND) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US53220K5048
LIGAND PHARMACEUTICALS INC financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 268.09 m USD |
| Operating income | 41.00 m USD |
| EBIT | 150.02 m USD |
| Net income | 124.45 m USD |
| Diluted EPS – continuing operations | 6.13 USD |
Full history since 1994, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About LIGAND PHARMACEUTICALS INC
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
More stocks
- FirstService Corp (FSV.TO)
- Castellum AB (CAST.ST)
- Trade Desk (The) (TTD)
- Telefonica Deutschland Holding (O2D.HM)
- POWELL INDUSTRIES INC (POWL)
- Huaibei Mining Holdings Co Ltd (600985.SS)
- Huali Industrial Group Company Limited (300979.SZ)
- CVR ENERGY INC (CVI)
- TERAWULF INC. (WULF)
- TKMS AG & Co KgaA (TKMS.DE)
- VORNADO REALTY TRUST (VNO)
- Taiwan Glass Ind Corp (1802.TW)
Not investment advice. All data without warranty, price as of 20.10.2026. Details in the risk notice.